Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewVac has signed a co-license agreement with Janssen Pharmaceutica to advance the development of quisinostat for the treatment of solid tumors in combination with standard of care agents.
Subscribe to our email newsletter
As per the deal, NewVac gains exclusive rights to develop and commercialize Janssen’s quisinostat in Russia and other Eastern European countries.
NewVac board chairman Nikolay Savchuk said the company was in search of a next generation HDAC compound with the potential to demonstrate clinical activity in solid tumors besides potential for clinically meaningful improvement of outcomes in resistant or refractory disease.
"NewVac will initiate solid tumor combination therapy studies which are accompanied by translational efforts," Savchuk added.
Janssen will contribute its knowledge in external global clinical trials to the development program.
The experimental drug candidate Quisinostat is a generation histone deacetylase inhibitor with antineoplastic activity.